HUYABIO International Announces Initiation of HBI-3000 Phase 2 Trial
HUYABIO International Announces Initiation of HBI-3000 Phase 2 Trial
San Diego, CA, USA – June 14, 2022 – HUYABIO International today announced that the first three patients had been dosed in an ongoing Phase 2 study of HUYABIO’s novel drug for pharmacological cardioversion of atrial fibrillation (AF).
Dr. Mireille Gillings, President, CEO & Executive Chair, said, “We are excited to proceed with dosing AF patients in our Phase 2 trial of HBI-3000.